Xinli Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xinli Lu has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
Yingying Wang
Department of AIDS Research, Hebei Key Laboratory of Pathogen and Epidemiology of Infectious Disease, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei 050021, China
11 shared publicationsMeng Liu
Department of AIDS Research, Hebei Key Laboratory of Pathogen and Epidemiology of Infectious Disease, Hebei Provincial Center for Disease Control and Prevention
9 shared publicationsNing An
Department of AIDS Research, Hebei Key Laboratory of Pathogen and Epidemiology of Infectious Disease, Hebei Provincial Center for Disease Control and Prevention
8 shared publicationsYan Li
Department of AIDS Research, Hebei Key Laboratory of Pathogen and Epidemiology of Infectious Disease, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei 050021, China
8 shared publicationsJuan Meng
Infection Division, The People's Hospital of Baoding, Baoding, Hebei, China
5 shared publicationsMiaomiao Su
Laboratory of Endocrinology, Baoding No. 1 Central Hospital, Baoding, China
5 shared publications
Latest Publications
- Open Access
- 13 May 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1823851
Pretreatment drug resistance profiles and transmission dynamics of HIV-1 among adults aged ≥50 in Hebei Province, China
Background: In China, the proportion of HIV-infected individuals aged ≥50 is rapidly increasing, yet limited research has focused on HIV transmission dynamics in this population. We investigated pretreatment drug resistance (PDR) and molecular transmission networks among older adults with HIV-1 in Hebei Province. Methods: From 2022 to 2025, 334 newly confirmed, ART-naïve HIV-1-infected individuals aged ≥50 with successful pol gene amplification were included. HIV-1 pol gene sequencing was performed, with drug resistance mutations and phenotypes determined via the Stanford HIV Drug Resistance Database. A molecular transmission network was constructed using a 1.5% genetic distance threshold. Results: The participants were predominantly male (80.2%), with contact between men who have sex with men (MSM) as the main transmission route (65.3%). CRF07_BC (42.5%) and CRF01_AE (38.0%) were dominant. The overall PDR prevalence was 12.3%, with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance being the most common (6.6%). The clustering rate was 35.0%. Multivariate analysis identified divorced/widowed status (adjusted odds ratio [aOR] = 2.040), residence in Eastern Hebei (aOR = 2.401), and CRF07_BC infection as independent risk factors for cluster inclusion. Notably, 77.8% of the participants were married, indicating potential spousal transmission through bisexual behavior. Conclusion: MSM is the predominant transmission route among older adults in Hebei. Marital dissolution drives active transmission cluster involvement, while the high proportion of married individuals underscores spousal transmission risk. Given the high PDR prevalence and specific vulnerabilities of older adults, transitioning to integrase strand transfer inhibitor (INSTI)-based regimens and targeted spousal interventions are urgent priorities.
- 13 May 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1823851
Open AccessPretreatment drug resistance profiles and transmission dynamics of HIV-1 among adults aged ≥50 in Hebei Province, China
Background: In China, the proportion of HIV-infected individuals aged ≥50 is rapidly increasing, yet limited research has focused on HIV transmission dynamics in this population. We investigated pretreatment drug resistance (PDR) and molecular transmission networks among older adults with HIV-1 in Hebei Province. Methods: From 2022 to 2025, 334 newly confirmed, ART-naïve HIV-1-infected individuals aged ≥50 with successful pol gene amplification were included. HIV-1 pol gene sequencing was performed, with drug resistance mutations and phenotypes determined via the Stanford HIV Drug Resistance Database. A molecular transmission network was constructed using a 1.5% genetic distance threshold. Results: The participants were predominantly male (80.2%), with contact between men who have sex with men (MSM) as the main transmission route (65.3%). CRF07_BC (42.5%) and CRF01_AE (38.0%) were dominant. The overall PDR prevalence was 12.3%, with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance being the most common (6.6%). The clustering rate was 35.0%. Multivariate analysis identified divorced/widowed status (adjusted odds ratio [aOR] = 2.040), residence in Eastern Hebei (aOR = 2.401), and CRF07_BC infection as independent risk factors for cluster inclusion. Notably, 77.8% of the participants were married, indicating potential spousal transmission through bisexual behavior. Conclusion: MSM is the predominant transmission route among older adults in Hebei. Marital dissolution drives active transmission cluster involvement, while the high proportion of married individuals underscores spousal transmission risk. Given the high PDR prevalence and specific vulnerabilities of older adults, transitioning to integrase strand transfer inhibitor (INSTI)-based regimens and targeted spousal interventions are urgent priorities.
- 1 April 2025
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 41 (4) , 220-224
Confirmation of Two Novel HIV-1 CRF01_AE/CRF07_BC Recombinant Forms Among Men Who Have Sex with Men in Hebei, China
Acquired immune deficiency syndrome caused by human immunodeficiency virus (HIV) is a serious infectious disease because of its' high genetic variability. Nowadays, homosexual contact has become the most predominant transmission route in Hebei province, China, leading to the emergence of novel HIV-1 recombinant forms. The neighbor-joining (N-J) phylogenetic trees were constructed using MEGA 6.0 in order to identify the subtypes of H22063 and H22144. Recombination breakpoints were identified using online resources jpHMM, RIP 3.0, and Simplot 3.5.1. In this study, we identified two novel HIV-1 unique recombinant forms (URFs) _0107 from three men who have sex with men in Hebei province, including H22063 and H22144. The near full-length genome analysis showed H22063 has seven gene recombination sub-regions, including three subtype CRF07_BC gene fragments inserted into the CRF01_AE backbone. H22144 has nine gene recombination sub-regions, including four subtype CRF07_BC gene fragments inserted into the CRF01_AE backbone. This study confirms the emergence of novel recombinant forms and suggests we should strengthen the monitoring of novel HIV recombinant forms in order to deal with the complex HIV-1 epidemiological trend in Hebei province, China.
- 1 April 2025
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 41 (4) , 220-224
Confirmation of Two Novel HIV-1 CRF01_AE/CRF07_BC Recombinant Forms Among Men Who Have Sex with Men in Hebei, China
Acquired immune deficiency syndrome caused by human immunodeficiency virus (HIV) is a serious infectious disease because of its' high genetic variability. Nowadays, homosexual contact has become the most predominant transmission route in Hebei province, China, leading to the emergence of novel HIV-1 recombinant forms. The neighbor-joining (N-J) phylogenetic trees were constructed using MEGA 6.0 in order to identify the subtypes of H22063 and H22144. Recombination breakpoints were identified using online resources jpHMM, RIP 3.0, and Simplot 3.5.1. In this study, we identified two novel HIV-1 unique recombinant forms (URFs) _0107 from three men who have sex with men in Hebei province, including H22063 and H22144. The near full-length genome analysis showed H22063 has seven gene recombination sub-regions, including three subtype CRF07_BC gene fragments inserted into the CRF01_AE backbone. H22144 has nine gene recombination sub-regions, including four subtype CRF07_BC gene fragments inserted into the CRF01_AE backbone. This study confirms the emergence of novel recombinant forms and suggests we should strengthen the monitoring of novel HIV recombinant forms in order to deal with the complex HIV-1 epidemiological trend in Hebei province, China.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 23 (1) , 53-57
Identification of a Novel HIV-1 Recombinant Form Comprising CRF01_AE and Subtype C in Hebei Province, China
Background: Circulating recombinant form (CRF) 01_AE and subtype C are two HIV-1 subtypes. In recent years, novel HIV-1 recombinant forms have become more and more prevalent in China; however, new HIV-1 CRF01_AE/C recombinant forms are less prevalent nationwide. Objective: Our study aimed to investigate new recombinant forms between different HIV-1 sub-types and evaluate their transmission risk among men who have sex with men (MSM) in Hebei, China. Methods: The near full-length genome (NFLG) of HIV-1 was identified using the analyses of the phylogenetic tree and gene breakpoints. Results: In the present work, we have reported a novel HIV-1 recombinant form composed of CRF01_AE and subtype C. The NFLG of this CRF01_AE/C form contained eight gene subre-gions, with four subtype C gene segments inserted into the CRF01_AE backbone, consisting of I CRF01_AE (790–1,171 nt), Ⅱ subtype C (1,172–1,840 nt), Ⅲ CRF01_AE (1,841–5,089 nt), Ⅳ subtype C (5,090–5,666 nt), Ⅴ CRF01_AE (5,667–6,317 nt), Ⅵ subtype C (6,318–8,586 nt), Ⅶ CRF01_AE (8,587–9,246 nt), and Ⅷ subtype C (9,247–9,409 nt). This new recombinant form was identified as CRF140_0107. Conclusion: The study suggested that it is important to monitor HIV-1 diversity to reduce HIV-1 transmission in China.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 23 (1) , 53-57
Identification of a Novel HIV-1 Recombinant Form Comprising CRF01_AE and Subtype C in Hebei Province, China
Background: Circulating recombinant form (CRF) 01_AE and subtype C are two HIV-1 subtypes. In recent years, novel HIV-1 recombinant forms have become more and more prevalent in China; however, new HIV-1 CRF01_AE/C recombinant forms are less prevalent nationwide. Objective: Our study aimed to investigate new recombinant forms between different HIV-1 sub-types and evaluate their transmission risk among men who have sex with men (MSM) in Hebei, China. Methods: The near full-length genome (NFLG) of HIV-1 was identified using the analyses of the phylogenetic tree and gene breakpoints. Results: In the present work, we have reported a novel HIV-1 recombinant form composed of CRF01_AE and subtype C. The NFLG of this CRF01_AE/C form contained eight gene subre-gions, with four subtype C gene segments inserted into the CRF01_AE backbone, consisting of I CRF01_AE (790–1,171 nt), Ⅱ subtype C (1,172–1,840 nt), Ⅲ CRF01_AE (1,841–5,089 nt), Ⅳ subtype C (5,090–5,666 nt), Ⅴ CRF01_AE (5,667–6,317 nt), Ⅵ subtype C (6,318–8,586 nt), Ⅶ CRF01_AE (8,587–9,246 nt), and Ⅷ subtype C (9,247–9,409 nt). This new recombinant form was identified as CRF140_0107. Conclusion: The study suggested that it is important to monitor HIV-1 diversity to reduce HIV-1 transmission in China.
- 27 August 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (6) , 1410-1421
Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023
Background: National treatment guidelines of China evolving necessitates population-level surveillance of transmitted drug resistance (TDR) to inform or update HIV treatment strategies. Methods: We analyzed the demographic, clinical, and virologic data obtained from people with HIV (PWH) residing in 31 provinces of China who were newly diagnosed between 2018 and 2023. Evidence of TDR was defined by the World Health Organization list for surveillance of drug resistance mutations. Results: Among the 22 124 PWH with protease and reverse transcriptase sequences, 965 (4.36%; 95% CI, 4.1–4.63) had at least 1 TDR mutation. The most frequent TDR mutations were nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.39%; 95% CI, 2.19%–2.59%), followed by nucleoside reverse transcriptase inhibitor mutations(1.35%; 95% CI, 1.2%–1.5%) and protease inhibitor mutations (1.12%; 95% CI, .98%–1.26%). The overall protease and reverse transcriptase TDR increased significantly from 4.05% (95% CI, 3.61%–4.52%) in 2018 to 5.39% (95% CI, 4.33%–6.57%) in 2023. A low level of integrase strand transfer inhibitor TDR was detected in 9 (0.21%; 95% CI, .1%–.38%) of 4205 PWH. Conclusions: Presently, the continued use of NNRTI-based first-line antiretroviral therapy regimen for HIV treatment has been justified.
- 27 August 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (6) , 1410-1421
Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023
Background: National treatment guidelines of China evolving necessitates population-level surveillance of transmitted drug resistance (TDR) to inform or update HIV treatment strategies. Methods: We analyzed the demographic, clinical, and virologic data obtained from people with HIV (PWH) residing in 31 provinces of China who were newly diagnosed between 2018 and 2023. Evidence of TDR was defined by the World Health Organization list for surveillance of drug resistance mutations. Results: Among the 22 124 PWH with protease and reverse transcriptase sequences, 965 (4.36%; 95% CI, 4.1–4.63) had at least 1 TDR mutation. The most frequent TDR mutations were nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.39%; 95% CI, 2.19%–2.59%), followed by nucleoside reverse transcriptase inhibitor mutations(1.35%; 95% CI, 1.2%–1.5%) and protease inhibitor mutations (1.12%; 95% CI, .98%–1.26%). The overall protease and reverse transcriptase TDR increased significantly from 4.05% (95% CI, 3.61%–4.52%) in 2018 to 5.39% (95% CI, 4.33%–6.57%) in 2023. A low level of integrase strand transfer inhibitor TDR was detected in 9 (0.21%; 95% CI, .1%–.38%) of 4205 PWH. Conclusions: Presently, the continued use of NNRTI-based first-line antiretroviral therapy regimen for HIV treatment has been justified.
- 26 August 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (5) , 1202-1214
Improvement in the 95-95-95 Targets Is Accompanied by a Reduction in Both the Human Immunodeficiency Virus Transmission Rate and Incidence in China
Background: In 2016, China has implemented the World Health Organization's “treat all” policy. We aimed to assess the impact of significant improvements in the 95-95-95 targets on population-level human immunodeficiency virus (HIV) transmission dynamics and incidence. Methods: We focused on 3 steps of the HIV care continuum: diagnosed, on antiretroviral therapy, and achieving viral suppression. The molecular transmission clusters were inferred using HIV-TRACE. New HIV infections were estimated using the incidence method in the European Centre for Disease Prevention and Control HIV Modelling Tool. Results: Between 2004 and 2023, the national HIV epidemiology database recorded 2.99 billion person-times of HIV tests and identified 1 976 878 new diagnoses. We noted a roughly “inverted-V” curve in the clustering frequency, with the peak recorded in 2014 (67.1% [95% confidence interval, 63.7%–70.5%]), concurrent with a significant improvement in the 95-95-95 targets from 10-13-<71 in 2005 to 84-93-97 in 2022. Furthermore, we observed a parabolic curve for a new infection with the vertex occurring in 2010. Conclusions: In general, it was suggested that the improvements in the 95-95-95 targets were accompanied by a reduction in both the population-level HIV transmission rate and incidence. Thus, China should allocate more effort to the first “95” target to achieve a balanced 95-95-95 target.
- 26 August 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (5) , 1202-1214
Improvement in the 95-95-95 Targets Is Accompanied by a Reduction in Both the Human Immunodeficiency Virus Transmission Rate and Incidence in China
Background: In 2016, China has implemented the World Health Organization's “treat all” policy. We aimed to assess the impact of significant improvements in the 95-95-95 targets on population-level human immunodeficiency virus (HIV) transmission dynamics and incidence. Methods: We focused on 3 steps of the HIV care continuum: diagnosed, on antiretroviral therapy, and achieving viral suppression. The molecular transmission clusters were inferred using HIV-TRACE. New HIV infections were estimated using the incidence method in the European Centre for Disease Prevention and Control HIV Modelling Tool. Results: Between 2004 and 2023, the national HIV epidemiology database recorded 2.99 billion person-times of HIV tests and identified 1 976 878 new diagnoses. We noted a roughly “inverted-V” curve in the clustering frequency, with the peak recorded in 2014 (67.1% [95% confidence interval, 63.7%–70.5%]), concurrent with a significant improvement in the 95-95-95 targets from 10-13-<71 in 2005 to 84-93-97 in 2022. Furthermore, we observed a parabolic curve for a new infection with the vertex occurring in 2010. Conclusions: In general, it was suggested that the improvements in the 95-95-95 targets were accompanied by a reduction in both the population-level HIV transmission rate and incidence. Thus, China should allocate more effort to the first “95” target to achieve a balanced 95-95-95 target.
- 22 August 2024
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 22 (5) , 1-10
Identification of Two HIV-1 CRF01_AE/B Recombinant Forms and a CRF01_AE/B/C Recombinant Form in Hebei Province, China
Background: In the Hebei province, Human Immunodeficiency Virus type one (HIV-1) recombinant strains of subtypes B, C, and CRF01_AE are emerging very rapidly and diversely. Objective: In order to confirm the characteristics of novel recombination forms, we aimed to analyze HIV-1 Near-full-length Genome sequences (NFLGs) obtained from three Men who have Sex with Men (MSM) in this study. Method: Phylogenetic trees were constructed and breakpoints analysis was performed based on the NFLGs and each gene fragment to examine the gene recombination patterns of three new HIV-1 NFLGs. Result: HIV-1 subtypes CRF01_AE and B were combined to generate the recombinant structures of the NFLGs 610 and 687. CRF01_AE, B, and C were combined to generate the recombinant structures of the NFLG 825. According to the NFLG phylogenetic tree, the NFLG 825 clustered with CRF65_cpx and the NFLGs 610 and 687 clustered with CRF68_01B. The recombination breakpoints analysis revealed that the recombination pattern of the NFLGs 610 and 687 was the insertion of subtype B fragment into the CRF01_AE backbone. Subregions I, II, and III were derived from CRF01_AE, subtype B, and CRF01_AE, respectively. The recombination pattern of the NFLG 825 contained ten fragments of subtypes CRF01_AE, C, and B. Finally, the above factors were formed using phylogenetic trees and breakpoints analysis, which were combined to get two CRF68_01B forms and one CRF65_cpx form. Conclusion: Our findings have suggested that it is crucial to keep an eye on the genetic diversity of HIV-1 in Hebei province.
- 22 August 2024
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 22 (5) , 1-10
Identification of Two HIV-1 CRF01_AE/B Recombinant Forms and a CRF01_AE/B/C Recombinant Form in Hebei Province, China
Background: In the Hebei province, Human Immunodeficiency Virus type one (HIV-1) recombinant strains of subtypes B, C, and CRF01_AE are emerging very rapidly and diversely. Objective: In order to confirm the characteristics of novel recombination forms, we aimed to analyze HIV-1 Near-full-length Genome sequences (NFLGs) obtained from three Men who have Sex with Men (MSM) in this study. Method: Phylogenetic trees were constructed and breakpoints analysis was performed based on the NFLGs and each gene fragment to examine the gene recombination patterns of three new HIV-1 NFLGs. Result: HIV-1 subtypes CRF01_AE and B were combined to generate the recombinant structures of the NFLGs 610 and 687. CRF01_AE, B, and C were combined to generate the recombinant structures of the NFLG 825. According to the NFLG phylogenetic tree, the NFLG 825 clustered with CRF65_cpx and the NFLGs 610 and 687 clustered with CRF68_01B. The recombination breakpoints analysis revealed that the recombination pattern of the NFLGs 610 and 687 was the insertion of subtype B fragment into the CRF01_AE backbone. Subregions I, II, and III were derived from CRF01_AE, subtype B, and CRF01_AE, respectively. The recombination pattern of the NFLG 825 contained ten fragments of subtypes CRF01_AE, C, and B. Finally, the above factors were formed using phylogenetic trees and breakpoints analysis, which were combined to get two CRF68_01B forms and one CRF65_cpx form. Conclusion: Our findings have suggested that it is crucial to keep an eye on the genetic diversity of HIV-1 in Hebei province.
- Open Access
- 8 June 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-5
Identification of a new HIV-1 circulating recombinant form (CRF159_01103) derived from CRF103_01B and CRF01_AE in Hebei Province, China
Recombinant HIV-1 genomes identified in three or more epidemiological unrelated individuals are defined as circulating recombinant forms (CRFs). CRFs can further recombine with other pure subtypes or recombinants to produce secondary recombinants. In this study, a new HIV-1 intersubtype CRF, designated CRF159_01103, isolated from three men who have sex with men with no epidemiological linkage, was identified in Baoding city, Hebei Province, China. CRF159_01103 was derived from CRF103_01B and CRF01_AE. Bayesian molecular clock analysis was performed on the CRF01-AE and CRF103_01B regions of CRF159_01103. The time of origin of CRF159_01103 was predicted to be 2018–2019, indicating that it is a recent recombinant virus. The emergence of CRF159_01103 has increased the complexity of the HIV-1 epidemic in Hebei Province.
- 8 June 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-5
Open AccessIdentification of a new HIV-1 circulating recombinant form (CRF159_01103) derived from CRF103_01B and CRF01_AE in Hebei Province, China
Recombinant HIV-1 genomes identified in three or more epidemiological unrelated individuals are defined as circulating recombinant forms (CRFs). CRFs can further recombine with other pure subtypes or recombinants to produce secondary recombinants. In this study, a new HIV-1 intersubtype CRF, designated CRF159_01103, isolated from three men who have sex with men with no epidemiological linkage, was identified in Baoding city, Hebei Province, China. CRF159_01103 was derived from CRF103_01B and CRF01_AE. Bayesian molecular clock analysis was performed on the CRF01-AE and CRF103_01B regions of CRF159_01103. The time of origin of CRF159_01103 was predicted to be 2018–2019, indicating that it is a recent recombinant virus. The emergence of CRF159_01103 has increased the complexity of the HIV-1 epidemic in Hebei Province.
- 24 May 2024
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 40 (5) , 257-262
Near-Full-Length Genome Analysis of a HIV-1 CRF01_AE/B Recombinant Strain Among Men Who Have Sex with Men in Chengde City, China
The unique recombinant form (URF) of HIV is formed by multiple subtypes which are cocirculating in some area, and the number of HIV recombinants is on the increase worldwide. In this study, we identified a URF named 2019638, composed of CRF01_AE and subtype B, in a man who has sex with men in Qinhuangdao, Hebei province, China. The near-full-length genome (NFLG) sequence was confirmed to be a novel URF. Within this NFLG, two CRF01_AE fragments were inserted into the pol and vif regions, respectively, using subtype B as the backbone. Moreover, the presence of the V106M and V179D point mutations in the reverse transcriptase (RT) region rendered the high-level resistance to efavirenz and nevirapine and intermediate resistance to doravirine. Our findings suggest that the HIV epidemic is evolving toward a high degree of recombination, and we need to continuously monitor HIV genetic diversity to control the further development of the AIDS epidemic.
- 24 May 2024
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 40 (5) , 257-262
Near-Full-Length Genome Analysis of a HIV-1 CRF01_AE/B Recombinant Strain Among Men Who Have Sex with Men in Chengde City, China
The unique recombinant form (URF) of HIV is formed by multiple subtypes which are cocirculating in some area, and the number of HIV recombinants is on the increase worldwide. In this study, we identified a URF named 2019638, composed of CRF01_AE and subtype B, in a man who has sex with men in Qinhuangdao, Hebei province, China. The near-full-length genome (NFLG) sequence was confirmed to be a novel URF. Within this NFLG, two CRF01_AE fragments were inserted into the pol and vif regions, respectively, using subtype B as the backbone. Moreover, the presence of the V106M and V179D point mutations in the reverse transcriptase (RT) region rendered the high-level resistance to efavirenz and nevirapine and intermediate resistance to doravirine. Our findings suggest that the HIV epidemic is evolving toward a high degree of recombination, and we need to continuously monitor HIV genetic diversity to control the further development of the AIDS epidemic.
- 29 December 2023
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 21 (4) , 232-239
Three Novel CRF01_AE/CRF07_BC Recombinant Forms of HIV-1 Identified in Shijiazhuang City, China
Background:: Hebei, a province with a low Human Immunodeficiency Virus (HIV) prevalence, is also a region with the most abundant HIV-1 genetic diversity. HIV-1 recombinant forms have been the key factor influencing the effectiveness of HIV-1 control and therapy. Objectives:: We aimed to study inter-subtype recombinant structures of new HIV-1-second generation recombinant forms. Methods:: Monitoring the HIV-1 subtype by phylogenetic and recombinant breakpoint analyses are the two most frequent methods among men who have sex with men (MSM). Here, three near full-length genomes (NFLGs) were obtained from HIV-1 seropositive MSM in Shijiazhuang City, China, who have never received antiretroviral therapy in 2021. Results:: Phylogenetic analysis indicated that three NFLGs were novel inter-subtype recombinant forms between CRF07_BC and CRF01_AE. For the NFLG 21S009, four CRF07_BC gene fragments were inserted into the pol, vif-vpr, vpu-env, and nef-3` LTR gene regions within a CRF01_ AE backbone, respectively. For the NFLG 21S095, four breakpoints were identified in HIV-1 pol and vpu regions. The NFLG 21S370 contained four gene recombinant breakpoints within HIV-1 pol and vpu-env gene regions. Of these three NFLGs, the NFLG 21S009 contained the most breakpoints, distributed in the pol, vif, vpr, vpu, env, and nef regions, respectively. In the gag-pol regions, three NFLGs had only one CRF07_BC gene fragment inserted into gene points between 4250 and 4792. Conclusion:: Our findings provide strong evidence that the surveillance of novel recombinant forms is necessary for the increase in better control of HIV.
- 29 December 2023
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 21 (4) , 232-239
Three Novel CRF01_AE/CRF07_BC Recombinant Forms of HIV-1 Identified in Shijiazhuang City, China
Background:: Hebei, a province with a low Human Immunodeficiency Virus (HIV) prevalence, is also a region with the most abundant HIV-1 genetic diversity. HIV-1 recombinant forms have been the key factor influencing the effectiveness of HIV-1 control and therapy. Objectives:: We aimed to study inter-subtype recombinant structures of new HIV-1-second generation recombinant forms. Methods:: Monitoring the HIV-1 subtype by phylogenetic and recombinant breakpoint analyses are the two most frequent methods among men who have sex with men (MSM). Here, three near full-length genomes (NFLGs) were obtained from HIV-1 seropositive MSM in Shijiazhuang City, China, who have never received antiretroviral therapy in 2021. Results:: Phylogenetic analysis indicated that three NFLGs were novel inter-subtype recombinant forms between CRF07_BC and CRF01_AE. For the NFLG 21S009, four CRF07_BC gene fragments were inserted into the pol, vif-vpr, vpu-env, and nef-3` LTR gene regions within a CRF01_ AE backbone, respectively. For the NFLG 21S095, four breakpoints were identified in HIV-1 pol and vpu regions. The NFLG 21S370 contained four gene recombinant breakpoints within HIV-1 pol and vpu-env gene regions. Of these three NFLGs, the NFLG 21S009 contained the most breakpoints, distributed in the pol, vif, vpr, vpu, env, and nef regions, respectively. In the gag-pol regions, three NFLGs had only one CRF07_BC gene fragment inserted into gene points between 4250 and 4792. Conclusion:: Our findings provide strong evidence that the surveillance of novel recombinant forms is necessary for the increase in better control of HIV.
- 3 October 2023
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 39 (10) , 558-566
Changes of Viral Load, Drug Resistance, and CD4 Cell Count in HIV-1–Infected Patients Receiving Antiretroviral Therapy in Hebei Province, China, 2003–2019
In this study, a total of 462 samples of whole blood were collected from 36 patients enrolled. During the entire course of antiretroviral therapy (ART) from 2003 to 2019, both the CD4 cell count and viral load (VL) of study patients were examined annually, and an HIV-1 genotypic drug resistance (DR) assay was carried out using an in-house method when the HIV-1 VL was >1,000 copies/mL. The results indicated that 13 (36.1%) experienced treatment failure and 23 (63.9%) experienced treatment success among 36 patients. The proportion of patients with effective treatment after the adjustment of ART regimens was significantly higher than before adjustment (χ 2 = 33.796, p < .001). Furthermore, the frequencies of HIV-1 DR mutations before adjustment were higher than those after adjustment ( t = 3.345, p = .002). In particular, among 23 patients with effective treatment after adjustment, the means ± standard deviations of the VLs and CD4 cell counts before adjustment were 3.85 ± 0.65 log RNA copies/mL and 226.83 ± 106.06 cells/mm 3 , respectively, compared with 2.19 ± 0.58 log RNA copies/mL and 367.68 ± 174.62 cells/mm 3 , respectively, after adjustment. Obviously, there were statistically significant differences in the changes in VL ( t = 8.728, p < .001) and CD4 cell count ( t = −4.476, p < .001) before and after adjustment. Therefore, patients who received updated ART regimens containing LPV/r and TDF after adjustment achieved better therapeutic effects compared with patients who received initial ART regimens harboring D4T/AZT or NVP. This suggests that future research is needed to initiate the surveillance of DR, VLs, and CD4 cell counts immediately after HIV diagnosis, and dynamic changes in these indicators so as to optimize ART effects.
- 3 October 2023
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 39 (10) , 558-566
Changes of Viral Load, Drug Resistance, and CD4 Cell Count in HIV-1–Infected Patients Receiving Antiretroviral Therapy in Hebei Province, China, 2003–2019
In this study, a total of 462 samples of whole blood were collected from 36 patients enrolled. During the entire course of antiretroviral therapy (ART) from 2003 to 2019, both the CD4 cell count and viral load (VL) of study patients were examined annually, and an HIV-1 genotypic drug resistance (DR) assay was carried out using an in-house method when the HIV-1 VL was >1,000 copies/mL. The results indicated that 13 (36.1%) experienced treatment failure and 23 (63.9%) experienced treatment success among 36 patients. The proportion of patients with effective treatment after the adjustment of ART regimens was significantly higher than before adjustment (χ 2 = 33.796, p < .001). Furthermore, the frequencies of HIV-1 DR mutations before adjustment were higher than those after adjustment ( t = 3.345, p = .002). In particular, among 23 patients with effective treatment after adjustment, the means ± standard deviations of the VLs and CD4 cell counts before adjustment were 3.85 ± 0.65 log RNA copies/mL and 226.83 ± 106.06 cells/mm 3 , respectively, compared with 2.19 ± 0.58 log RNA copies/mL and 367.68 ± 174.62 cells/mm 3 , respectively, after adjustment. Obviously, there were statistically significant differences in the changes in VL ( t = 8.728, p < .001) and CD4 cell count ( t = −4.476, p < .001) before and after adjustment. Therefore, patients who received updated ART regimens containing LPV/r and TDF after adjustment achieved better therapeutic effects compared with patients who received initial ART regimens harboring D4T/AZT or NVP. This suggests that future research is needed to initiate the surveillance of DR, VLs, and CD4 cell counts immediately after HIV diagnosis, and dynamic changes in these indicators so as to optimize ART effects.